Investment
Features
FeesSafety
Academy
More
Pluang+

Putnam Focused Large Cap Value ETF upgraded to 'buy' after 36.66% return since Oct 2024

Analyst Insights
08 Jun 2026
Seeking Alpha
View Source
Bullish
pluang ai news

The Putnam Focused Large Cap Value ETF (PVAL) has been upgraded from 'hold' to 'buy' following a strong 36.66% total return since October 2024. The ETF is praised for its strong momentum, solid medium-term earnings growth with a 21.82% EPS CAGR, and effective risk management through sector diversification and mixed-beta positions. Despite a forward P/E ratio of 15.36x and some quality concerns, PVAL's active management and portfolio construction have delivered superior risk-adjusted returns compared to peers and the SPY index. With a 0.55% expense ratio and a declining yield, PVAL remains a growth-oriented investment with a unique blend of value, momentum, and diversification that justifies the upgrade to a 'buy' rating.

More News

Barclays raises Hudbay Minerals price target to $32 on strong copper growth outlook.

Barclays raises Hudbay Minerals price target to $32 on strong copper growth outlook.

Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...

Analyst Insights
Bullish
45 minutes ago
Morgan Stanley beats Q2 earnings and revenue estimates with strong divisional growth.

Morgan Stanley beats Q2 earnings and revenue estimates with strong divisional growth.

Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...

Company Fundamentals
Bullish
48 minutes ago
Autoimmune therapeutics market to reach $137.85B by 2035, driven by biologics and precision medicine growth

Autoimmune therapeutics market to reach $137.85B by 2035, driven by biologics and precision medicine growth

The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...

Market News
Bullish
48 minutes ago
Light Up Chinatown! 2026 festival returns to Vancouver with food, music, and community events on August 8-9.

Light Up Chinatown! 2026 festival returns to Vancouver with food, music, and community events on August 8-9.

The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...

Others
Neutral
48 minutes ago
Travelers are more strategic with rewards programs, seeking value and ease amid rising loyalty challenges.

Travelers are more strategic with rewards programs, seeking value and ease amid rising loyalty challenges.

New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...

Others
Neutral
48 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App